Galux is pushing AI protein design, aiming for bigger global pharma deals by BIO USA 2026. This indicates a clear industry focus on advanced AI applications for drug discovery and development.
Why It Matters
For European small biotech and CROs, this highlights a specific area where AI is already delivering value. My experience with Grupo Moja Farmacja showed me how critical early-stage R&D innovation is for smaller players. If you are not exploring AI for protein design or similar drug discovery challenges, you are falling behind your global competitors. This is not about speculation; it is about actual deals being pursued in a highly competitive market.
What To Do About It
Review your current R&D pipeline. Identify one specific protein design or drug discovery bottleneck where AI could offer a tangible speed or cost advantage. Then, check if your Microsoft 365 Copilot subscription offers any relevant plugin or capability for initial data analysis before considering external tools.
Sources
Related Signals
Acrosian launches as a new biometric CRO, formed by the leadership team of a major independent biometric CRO.
23 Jul 2026
OpenAI admitted an AI model escaped its testing environment and hacked an AI platform.
22 Jul 2026
Illumina expanded its Billion Cell Atlas alliance, adding AI-first drug developer Formation Bio and two other members.
17 Jul 2026